Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Saad Z. Usmani"'
Autor:
Liat Shargian-Alon, Moshe Yeshurun, Hira S. Mian, Hillard M. Lazarus, Shaji Kumar, Baldeep Wirk, Sagar S. Patel, Patrick Hagen, Sunita Nathan, Ricardo D. Parrondo, Naresh Bumma, Leona Holmberg, Mark A. Schroeder, Cindy Lee, Oren Pasvolsky, Nina Shah, Uri Rozovski, Saad Z. Usmani, Noel Estrada-Merly, Arnon Nagler, Trent P Wang, Taiga Nishihori, Muzaffar H. Qazilbash, Rahul Banerjee, Kevin C. Miller, Robert Peter Gale, Nasheed Hossain, Raphael Fraser, Amer Assal, Anita D'Souza
Publikováno v:
Bone Marrow Transplant
The role of maintenance therapy after high-dose chemotherapy and first autologous transplantation in multiple myeloma (MM) is well established. We explored the effect of maintenance therapy on outcomes after salvage second autologous hematopoietic ce
Autor:
Douglas W. Sborov, Paul G. Richardson, Noopur Raje, Anita D'Souza, Rao Saleem, Frank Campana, Franck Dubin, Jacob P. Laubach, Giada Bianchi, Sascha A. Tuchman, Dheepak Kanagavel, Saad Z. Usmani, William I. Bensinger, Chatchada Karanes
Publikováno v:
Leukemia
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone (Pd) in relapsed/refra
Autor:
Hans C. Lee, Saad Z. Usmani, Robert M. Rifkin, Dasha Cherepanov, Evangelos Terpos, Faith E. Davies, Dorothy Romanus, Antonio Palumbo, Aditya Raju, Jesus G. Berdeja, Dawn Marie Stull, Noemi Puig, Jorge Vela-Ojeda, Rafat Abonour, Xavier Leleu, Hui Huang, Ajai Chari, Eileen Farrelly, Mario Boccadoro, Gordon Cook, Katja Weisel, Gareth J. Morgan, Caitlin Costello, Jeffrey A. Zonder, Marlo Blazer, Michael A. Thompson, Roman Hájek
Publikováno v:
Annals of Hematology
Multiple available combinations of proteasome inhibitors, immunomodulators (IMIDs), and monoclonal antibodies are shifting the relapsed/refractory multiple myeloma (RRMM) treatment landscape. Lack of head-to-head trials of triplet regimens highlights
Autor:
Manisha Bhutani, Myra M. Robinson, Shebli Atrash, Jordan Robinson, Daniel Slaughter, Kristen Cassetta, Ami Ndiaye, Saad Z. Usmani, Barry Paul, Peter M. Voorhees
Publikováno v:
Blood. 136:11-13
Background: Targeting B-cell maturation antigen (BCMA) with antibody-drug conjugates (ADCs), bispecific antibodies, or chimeric antigen receptor t-cells (CAR-Ts) has proven safe and effective in recent clinical trials, but relapses remain common. As
Autor:
Saad Z. Usmani, Natalia Neparidze, Adam Rosenthal, Terri L. Parker, Erica L. Campagnaro, Prashant Kapoor, Shayna Sarosiek, Antje Hoering, Vaishali Sanchorawala, Patrick Hagen, Emma C. Scott, Robert Z. Orlowski, Brian G.M. Durie, Heather Landau
Publikováno v:
Blood. 136:20-21
Background: Isatuximab (SAR650984) is an IgG1k monoclonal antibody that binds with high affinity to CD38 expressed on plasma cells in AL amyloidosis. It has been shown to be efficacious and well tolerated in relapsed and refractory multiple myeloma a
Autor:
Saad Z. Usmani, Myra M. Robinson, Reed Friend, Mauricio Pineda-Roman, Shebli Atrash, Jordan Robinson, Peter M. Voorhees, Barry Paul, Ami Ndiaye, James T. Symanowski, Manisha Bhutani
Publikováno v:
Journal of Clinical Oncology. 39:e20011-e20011
e20011 Background: Multiple Myeloma (MM) is an incurable malignancy of terminally differentiated plasma cells. The combination of pomalidomide/dexamethasone with either daratumumab or isatuximab is FDA approved for relapsed refractory multiple myelom
Autor:
Nushmia Z. Khokhar, Hareth Nahi, Neil Rabin, Donna E. Reece, Nizar J. Bahlis, Meletios A. Dimopoulos, Philippe Moreau, Jesús F. San-Miguel, Hartmut Goldschmidt, Albert Oriol, Dina Ben Yehuda, Saad Z. Usmani, Lisa O'Rourke, Christopher Chiu, Sung-Soo Yoon, Mieczysław Komarnicki, Xiang Qin, Paul G. Richardson, Tahamtan Ahmadi, Mary E. Guckert, Kenshi Suzuki, Steen Lisby, Torben Plesner, Robert Z. Orlowski
Publikováno v:
Dimopoulos, M A, Oriol, A, Nahi, H, San-Miguel, J, Bahlis, N J, Usmani, S Z, Rabin, N, Orlowski, R Z, Komarnicki, M, Suzuki, K, Plesner, T, Yoon, S-S, Ben Yehuda, D, Richardson, P G, Goldschmidt, H, Reece, D, Lisby, S, Khokhar, N Z, O'Rourke, L, Chiu, C, Qin, X, Guckert, M, Ahmadi, T, Moreau, P & POLLUX Investigators 2016, ' Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma ', The New England Journal of Medicine, vol. 375, no. 14, pp. 1319-1331 . https://doi.org/10.1056/NEJMoa1607751
Background Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma. Methods In this phase 3 trial, we randomly assigned 569 patients with
Autor:
Saad Z. Usmani, William I. Bensinger, Noopur Raje, Dheepak Kanagavel, Qianying Liu, Frank Campana, Chatchada Karanes, Dorothée Semiond, Paul G. Richardson, Kenneth C. Anderson, Franck Dubin, Joseph Mikhael
Publikováno v:
Blood. 134(2)
This phase 1b dose-escalation study evaluated isatuximab plus pomalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Patients who had received ≥2 prior MM therapies, including lenalidomide and a proteasome inhibito
Autor:
Shebli Atrash, Saad Z. Usmani, Peter M. Voorhees, Mauricio Pineda-Roman, Issam Hamadeh, James T. Symanowski, Justin Arnall, Myra M. Robinson, M. Junaid Hussain, Manisha Bhutani, Reed Friend
Publikováno v:
British journal of haematology. 186(1)
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 25(4)
Systemic light-chain (AL) amyloidosis is a rare hematologic disorder where proteins infiltrate tissues leading to organ failure and death. Cardiac involvement, present in ∼70% of patients, determines stage and prognosis of the disease, with advance